

---

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services. The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

DIGEST

SB 43 Original

2026 Regular Session

McMath

Proposed law establishes the Psychedelic-Assisted Therapy Program within the La. Dept. of Health, office of behavioral health.

Proposed law establishes the following purposes of the program:

- (1) To assist academic health centers in conducting clinical studies for use of psychedelic-assisted therapy involving ibogaine and psilocybin for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
- (2) To utilize the human service districts and authorities to identify eligible patients to participate in the program.
- (3) To allow parishes to utilize opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies.

Proposed law requires the La. Dept. of Health to approve academic health centers to participate in the program if a center has submitted documentation ensuring compliance with state and federal regulations as provided in proposed law.

Proposed law requires the department to utilize the human service districts and authorities to identify eligible participants and to establish a process to allow parishes to utilize opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies.

Proposed law authorizes the department to seek and receive federal funds, gifts, grants, and donations for the program in addition to utilizing opioid settlement funds.

Proposed law requires participating academic health centers to submit an annual progress report to the department and requires the department to submit a compiled report to the legislature by Feb. 1st of each year.

Proposed law requires the department and participating academic health centers to coordinate with other states that are conducting clinical trials for use of psychedelic-assisted therapy to the extent feasible.

Effective August 1, 2026.

(Adds R.S. 28:211)